Pfizer Inc. safe stock for beginners with cancer treatment expansion

Pfizer Inc. (NYSE:PFE) has expanded its cancer treatment portfolio, driving bullish sentiment among investors. On June 8, 2026, Pfizer received FDA approval to expand the use of its drug Hympavzi for hemophilia patients, adding to its growing cancer treatment offerings following the $43 billion acquisition of Seagen. Pfizer's first-quarter 2026 results, released on May 5, showed a 2% operational revenue increase to $14.5 billion, driven by strong performances from newer products and top-selling drugs like Eliquis.

The pharmaceutical sector and investors focused on longevity and safety stocks are impacted. Pfizer's expansion into cancer treatments has attracted hedge funds, with 25 of the 60 most recent 13F filers holding the stock. The company's safe-haven status and dividend history make it an attractive choice for beginners, ranking 14th in a list of 15 safe stocks. However, some investors question whether Pfizer's valuation reflects a generational opportunity or a value trap.

Upcoming catalysts to watch are Pfizer's earnings releases and regulatory decisions. Pfizer is scheduled to report second-quarter earnings on July 29, 2026, followed by third-quarter results on October 28. Additionally, investors await regulatory decisions on Pfizer's pipeline of cancer treatments and other drugs, which could further drive the narrative around the company's growth prospects.